Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug

Vera Therapeutics' stock increased following FDA approval of Trutakna, a $425,000-per-year drug targeting BAFF and APRIL proteins for IgA nephropathy. The drug is the first in the U.S. to address both proteins linked to the condition.